
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
This trial compared olaparib with enzalutamide or abiraterone for men with prostate cancer that had spread to other parts of the body.
It was for men who’d:
This trial was open for people to join between May and September 2018. The results were published in a journal in 2020 and on the pharmacy company’s website in 2021.
The team found that men with advanced prostate cancer who had olaparib lived longer before their cancer got worse.
About this trial
This was a phase 3 trial. It was a . The people who took part were in 2 groups. Neither they nor their doctor chose which group they were in.
Of the 387 people who took part:
Results
The team looked at how long it took for the cancer to get worse. They found that the time it took was:
Quality of life
After a year of treatment the team looked at pain. They wanted to know the number of people whose pain had not got worse. They found it was:
Side effects
There were more severe side effects with olaparib than with either enzalutamide or abiraterone.
The most common side effects overall for olaparib were:
The most common side effects overall for enzalutamide or abiraterone were:
Conclusion
The trial team concluded that olaparib worked better than enzalutamide or abiraterone for men:
When compared with enzalutamide and abiraterone, olaparib:
Researchers are looking at olaparib in further trials.
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists () and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Johann de Bono
AstraZeneca
Freephone 0808 800 4040
"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”